Cancer Research Blog

Bringing You the Latest in the Search For a Cure

Month: September 2015

FDA Approves Sonidegib for Some Patients with Advanced Basal Cell Carcinoma

On July 24, the Food and Drug Administration (FDA) approved sonidegib (Odomzo®) to treat some patients with basal cell carcinoma (BCC), the most common form of non-melanoma skin cancer.

The approval is for patients with a rare type of BCC that has become locally advanced because it has returned after prior surgery or radiation or whose cancer is not amenable to surgery or radiation.

Intraperitoneal Chemotherapy in Advanced Ovarian Cancer Improves Survival, But Is Underused

Combining intraperitoneal (IP) chemotherapy with intravenous (IV) chemotherapy improves survival in women with advanced ovarian cancer, though its use in clinical practice has been limited, according to findings from a new study.

Published August 3 in the Journal of Clinical Oncology, the prospective cohort study found that, compared with IV chemotherapy alone, treatment with both IP and IV chemotherapy was associated with improved 3-year overall survival in women with stage III ovarian cancer who, after surgery, had only very small tumor deposits remaining (1 cm or less in size). IP chemotherapy was used in less than half of women in the study.

NCI Initiative to Speed Development of Childhood Cancer Therapies

NCI has awarded grants to five research teams to participate in its Pediatric Preclinical Testing Consortium (PPTC).

The PPTC is designed to address an important barrier to developing new drugs for the treatment of childhood cancers: producing reliable data from studies involving laboratory and animal models—often referred to as preclinical models—that can help to prioritize which agents to pursue in human clinical trials.

Researcher Interview: Tom Hudson

Tom Hudson, M.D., President and Scientific Director of the Ontario Institute for Cancer Research (OICR), Chair of the Executive Committee for the International Cancer Genome Consortium (ICGC) and Member for the Global Alliance for Genomics and Health spoke with Emma J. Spaulding, M.P.H., for this Researcher Interview.

Emma Spaulding (ES): Can you explain the ICGC and describe the most exciting projects happening there right now?

FDA Approves Rolapitant to Prevent Nausea and Vomiting from Chemotherapy

On September 1, the Food and Drug Administration (FDA) approved rolapitant (Varubi®) to prevent delayed phase chemotherapy-induced nausea and vomiting in adult cancer patients. The approval is for the use of rolapitant in combination with two other antiemetic drugs given during initial or repeated courses of vomit-inducing chemotherapy.

Delayed phase nausea and vomiting—generally defined as nausea or vomiting that occurs from 24 to 120 hours or more after a course of chemotherapy—tends to be under-reported and thus underestimated, explained Ann O’Mara, Ph.D., head of Palliative Care Research in NCI’s Division of Cancer Prevention.

Study Identifies Biomarker that Detects Early Pancreatic Cancer

Due to the lack of reliable biomarkers to screen for pancreatic cancer, as many as 80% of pancreatic cancers are metastatic when diagnosed, leading to very poor prognoses.  

Researchers from the University of Texas MD Anderson Cancer Center have identified a protein marker that is found at much higher levels in exosomes that derive from cancer cells compared to healthy cells, a discovery that may improve the detection and treatment of pancreatic cancer. 

Improving Chronic Disease in the Caribbean through Evidence-based Behavioral and Social Interventions

The Office for Behavioral and Social Sciences Research and the NCI’s Center for Global Health held a workshop entitled “Improving Chronic Disease in the Caribbean through Evidence-based Behavioral and Social Interventions”, which took place in Bridgetown, Barbados from July 21 to 24, 2015.   The objectives of the workshop were to encourage the generation of research to more rapidly accelerate chronic disease prevention and management Additional objectives included bridging existing gaps in chronic disease etiology, prevention, screening, treatment, and health disparities in relation to race, socioeconomic status, religious background, and gender inequality.  Other participating NIH ICs included National Institute for Alcohol Abuse and Alcoholism, National Heart, Lung and Blood Institute, National Institute on Drug Abuse, National Center for Complementary and Integrative Health, Fogarty International Center and the Center for Scientific Review.  Regional Caribbean partners included the Chronic Disease Research Centre (CDRC) of the University of West Indies at Cave Hill and the Caribbean Public Health Agency (CARPHA).

Honorable Minister of Health, Dr. John Boyce delivered a dynamic keynote in which he revealed plans for Barbados to tackle non-communicable diseases (NCDs).   Workshop program included presentations on US-Caribbean Health Disparities (Dr. Ian Hambleton, CDRC); Chronic Disease Surveillance in the Caribbean (Ms. Angela Rose, CDRC); Surveillance of NCDs in the Caribbean with Implications for CARICOM countries (Glennis Andall-Brereton, CARPHA); Cancer Control and Prevention in the Caribbean (Dr. Damali Martin, NCI); Community Engagement of Culturally Tailored Interventions (Ms. Dana Sampson, OBSSR); and Translation Research and Implementation Science for Chronic Disease Advancement (Uche Sampson, NHLBI).  Additional sessions included a panel discussion on proper collection of data for epidemiology research, and break-out sessions on cervical cancer, physical activity, alcohol abuse and tobacco us, diet and nutrition, health literacy, treatment adherence, complementary medicine, diabetes and hypertension.  Further presentations on US-Caribbean collaboration for cancer and diabetes research and on the NIH grant process were also covered on the second and third days of the workshop. 

Cancer Research Blog © 2016
Frontier Theme